Editas Medicine, Inc. Share Price & Technical Analysis
EDIT · $2.65 (0.00%)
Healthcare / Biotechnology
$2.65
0.00%
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The …
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-21% return in Jun, 0% avg return in past 3 year Jun month.
40% return in 2026, -18% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 10% | 19% | 20% | 17% | -21% | – | – | – | – | – | – | 40% |
| 25 | 0% | 46% | -40% | 45% | 0% | 22% | 14% | 4% | 40% | -11% | -23% | -17% | 81% |
| 24 | -30% | 42% | -27% | -30% | 0% | -11% | 15% | -31% | -8% | -15% | -24% | -41% | -160% |
| 23 | 9% | -13% | -20% | 14% | 14% | -11% | 6% | 2% | -13% | -14% | 57% | -5% | 26% |
| 22 | -29% | -11% | 0% | -32% | -14% | 2% | 35% | -7% | -16% | 1% | -18% | -16% | -105% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$407.44M
P/E ratio
—
52W high
$4.54
52W low
$1.66
Volume
18,49,925
Beta
2.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Editas Medicine, Inc. share price today?
- Editas Medicine, Inc. (EDIT) last traded around $2.65 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does EDIT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for EDIT. Download the app for real-time alerts.
- How can I analyze Editas Medicine, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.